Barbui T, De Steano V, Ghirardi A, et al. Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in polycythemia vera. Blood Cancer J. 2018;8:124.
Bewersdorf JP, Jaszczur SM, Afifi S, et al. Beyond ruxolitinib: fedratinib and other emergent treatment options for myelofibrosis. Cancer Manag Res. 2019;11:10777-10790.
Bose P, Daver N, Pemmaraju N, et al. Sotatercept (ACE-011) alone and in combination with ruxolitinib in patients (pts) with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and anemia. Blood. 2017;130:Abstract 255.
Gisslinger H, Klade C, Georgiav P, et al. Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial. Blood. 2017;130:Abstract 320.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762-1769.
Harrison CN, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787-798.
Inrebic® (fedratinib) [prescribing information]. Celgene Corporation. Approved 2019. Revised August 2019.
Jakafi® (ruxolitinib) [prescribing information]. Incyte Corporation. Approved 2011. Revised January 2020.
Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007:7;673-683.
Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652-659.
Mesa RA, Vannucchi A, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4:e225-e236.
National Comprehensive Cancer Network (NCCN). Myeloproliferative neoplasms (Version 1.2020). Published May 21, 2020. Accessed September 30, 2020. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT04173494. A study of momelotinib versus danazol in symptomatic and anemic myelofibrosis patients (MOMENTUM). Updated September 28, 2020. Accessed September 30, 2020. https://clinicaltrials.gov/ct2/show/NCT04173494
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT03194542. A safety and efficacy study to evaluate luspatercept in subjects with myeloproliferative neoplasm-associated myelofibrosis who have anemia with and without red blood cell-transfusion dependence. Updated February 27, 2020. Accessed September 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03194542
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT02158858. A phase 2 study of CPI-0610 with and without ruxolitinib in patients with myelofibrosis. Updated October 30, 2019. Accessed September 30, 2020. https://clinicaltrials.gov/ct2/show/NCT02158858
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT03144687. A study of itacitinib in combination with low-dose ruxolitinib or itacitinib alone following ruxolitinib in subjects with myelofibrosis. Updated September 11, 2020. Accessed September 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03144687
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT01981850. A phase 2 study of PRM-151 in subjects with myelofibrosis. Updated September 11, 2020. Accessed September 30, 2020.
National Institutes of Health [NIH] website. ClinicalTrials.gov identifier: NCT03895112. MPN-RC 118 AVID200 in myelofibrosis. Updated June 2, 2020. Accessed September 30, 2020. https://clinicaltrials.gov/ct2/show/NCT03895112
Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis. A randomized clinical trial. JAMA Oncol. 2015;1:643-651.
Pardanani A, Tefferi A. How I treat myelofibrosis after failure of JAK inhibitors. Blood. 2018;132:492-500.
Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132:694-706.
Rampal R, Verstovsek S, Devlin S, et al. Early results of a phase II study of combined ruxolitinib and thalidomide in patients with myelofibrosis. HemaSphere. 2019;3(S1):Abstract PS1467.
Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680-692.
Stegelmann F, Koschmieder S, Hochhaus A, et al. Ruxolitinib plus pomalidomide in myelofibrosis with anemia: results from the MPNSG-0212 combination trial (NCT01644110). HemaSphere. 2019;3(S1):Abstract S1608.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:94-108.
Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426-435.
Vannuchi AM, Guglielmelli P, et al. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematol Am Soc Hematol Educ Program. 2017;1:480-488.
Verstovsek S, Mesa R, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Patricia Manea, BSN, RN, CCRP

Project Manager, Hematology and Phase I Clinical Trials
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas

Disclosures

Disclosure: Patricia Manea, BSN, RN, CCRP, has disclosed no relevant financial relationships.

Editor

Davecia R. Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CE

Enhancing Outcomes in Patients With Myeloproliferative Neoplasms: Practical Application for Nurses

Authors: Patricia Manea, BSN, RN, CCRP
CE Released: 10/14/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 10/14/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses and other clinicians involved in the care of patients with myeloproliferative neoplasms.

The goal of this activity is to improve oncology nurses' ability to differentiate among myeloproliferative neoplasms (MPNs), personalize treatment options, monitor for and treat adverse events, and provide appropriate counseling in order to enhance outcomes for patients with MPNs.

Upon completion of this activity, participants will:

Increased knowledge regarding the
- Emerging MPN treatments
Greater competence related to
- Discussing the potential side effects of MPN treatment options with patients
- Mitigating common treatment-related adverse effects in patients with MPNs
Demonstrating greater confidence in their ability to
- Providing key counseling points to patients with MPNs about their treatment

Disclosures

Faculty

Patricia Manea, BSN, RN, CCRP

Project Manager, Hematology and Phase I Clinical Trials
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas

Disclosures

Disclosure: Patricia Manea, BSN, RN, CCRP, has disclosed no relevant financial relationships.

Editor

Davecia R. Cameron, MS

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Davecia R. Cameron, MS, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

The Nurse View: A Clinical Resource for Oncology Nurses

From Medscape Education Oncology

Enhancing Outcomes in Patients With Myeloproliferative Neoplasms: Practical Application for Nurses

Authors: Patricia Manea, BSN, RN, CCRPFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CE Released: 10/14/2020

Valid for credit through: 10/14/2021

processing....

AE = adverse event
ASA = acetylsalicylic acid
ASH = American Society of Hematology
basos = basophils
BAT = best available therapy
BID = twice daily
BM = bone marrow
BMBx = bone marrow biopsy
CBC = complete blood count
CAD = coronary artery disease
CHF = congestive heart failure
CHR = complete hematologic response
CI = clinical improvement
CI = confidence interval
CML = chronic lymphocytic leukemia
CMR = complete molecular response
CR = complete response
CT = computed tomography
CV = cardiovascular
CVA = cerebrovascular accident
D/C = discontinuation
DIPSS = Dynamic International Prognostic Scoring System
DIPSS-Plus = Dynamic International Prognostic Scoring System-Plus
DM = diabetes mellitus
DVT = deep vein thrombosis
ELN = European LeukemiaNet
EMH = extramedullary hematopoiesis
eos = eosinophils
EPO = erythropoietin
ESA = erythropoiesis-stimulating agents
ET = essential thrombocythemia
FDA = US Food and Drug Administration
FEDR = fedratinib
FU = follow-up
GERD = gastroesophageal reflux disease
GI = gastrointestinal
Hep B = hepatitis B
HCP = healthcare provider
HCT = hematopoietic cell transplantation
Hct = hematocrit
Hgb = hemoglobin
HTN = hypertension
HR = hazard ratio
HSC = hematopoietic stem cell
HSCT = hematopoietic stem cell transplantation
HSV = herpes simplex virus
HU = hydroxyurea
IFN = interferon
IMiD = immunomodulatory drug
IPSET = International Prognostic Score for Thrombosis in Essential Thrombocythemia
IPSS = International Prognostic Scoring System
ITT = intent to treat
IWG-MRT = International Working Group-Myeloproliferative Neoplasms Research and Treatment
JAKi = JAK inhibitor
LCM = left costal margin
LDH = lactate dehydrogenase
LE = lower extremity
LFT = liver function test
LLS = Leukemia & Lymphoma Society
LMWH = low-molecular-weight heparin
lymph = lymphocytes
MDS = myelodysplastic syndrome
MF = myelofibrosis
MI = myocardial infarction
MNC = mononuclear cells
MOA = mechanism of action
monos = monocytes
MPD = myeloproliferative disorder
MPN = myeloproliferative neoplasm
MPN-SAF = Myeloproliferative Neoplasm Symptom Assessment Score
MRD = minimal residual disease
MRI = magnetic resonance imaging
NA = not applicable
NCCN = National Comprehensive Cancer Network
NGS = next-generation sequencing
OS = overall survival
PAC = pacritinib
PB = peripheral blood
PCP = primary care provider
PCR = polymerase chain reaction
PE = pulmonary embolism
plt = platelet
PMF = primary myelofibrosis
PMHx = past medical history
PMN = polymorphonuclear leukocyte
PR = partial response
PRBC = packed red blood cell
PS = performance status
PTX-2 = pentraxin-2
PV = polycythemia vera
QD = every day
QoL = quality of life
R = randomized
RBC = red blood cell
rINFa = recombinant interferon alfa
ropeg = ropeginterferon alfa-2b
RPSFT = rank-preserving structural failure time
RR = relative risk
RUX = ruxolitinib
ruxo = ruxolitnib
SC = subcutaneous
SOC = standard of care
SVR = splenic volume reduction
SVRR = splenic volume reduction rate
TB = tuberculosis
TEAE = treatment-emergent adverse event
TRAE = treatment-related adverse event
TSS = total symptom score
ULN = upper limit of normal
UNL = upper normal limit
URI = upper respiratory infection
UTI = urinary tract infection
VAF = variant allele frequency
VWD = von Willebrand disease
VZV = varicella-zoster virus
WBC = white blood cell
WHO = World Health Organization